United Therapeutics (NASDAQ: UTHR) CEO sells shares in prearranged plan

Posted by Trevor Kearing on Oct 24th, 2026

What happened

United Therapeutics Corp (NASDAQ: UTHR) said Martine A. Rothblatt sold 9,500 shares on 2026-10-22. Rothblatt is the chairperson, CEO and a director. The filing says the shares came from stock options exercised the same day and were sold under a Rule 10b5-1 trading plan.

The options had a $117.76 exercise price. The shares sold in multiple trades at $562.97 to $590.40 per share. The reported sale totaled about $5.54 million. After the sale, Rothblatt held 324,443 shares through family trusts.

Key numbers

Metric	Latest	Source
Shares sold	9,500 shares	SEC Form 4
Sale price range	from $562.97 to $590.40 per share	SEC Form 4
Total sale value	about $5.54 million	SEC Form 4
Shares held after sale	324,443 shares	SEC Form 4
Pre-sale holding	333,943 shares	SEC Form 4

Why it matters

OptimistFi's case is that United Therapeuticals depends on Tyvaso-led pulmonary hypertension cash flows staying durable enough to fund the next growth leg before competition or pricing pressure erodes the franchise. This filing leaves that view unchanged. It reports a prearranged insider sale, not a new operating signal. The 9,500 shares were about 2.8% of the 333,943 shares held before the sale.

The filing also says the trades came from same-day option exercises. The sale price range was far above the $117.76 exercise price. That points to a structured trade, not a simple open-market exit. The filing says the sales ran through a Rule 10b5-1 trading plan, which limits how much investors should read into the trade direction.

The reported sale reduced the stake, but it did not remove it. Rothblatt still held 324,443 shares after the sale, and the filing ties those shares to family trusts. For investors, the main takeaway is ownership change, not a fresh business update.

The filing gives a clear snapshot of one insider event on 2026-10-22. It lists the role, trade size, price range, total value and post-sale holding, all of which investors can verify directly.

Stock perps: every US stock that trades as a perpetual future, by leverage, live

What's next

The filing says the 10b5-1 plan adopted on November 7, 2025 continues until the earlier of exercise of 1,734,410 stock options or December 31, 2026. Any additional Form 4 sales before then would show the preset plan is still running.

The stock options expire on March 15, 2027, so the plan ends first if the trading schedule runs its course. No more sales before December 31, 2026 would leave this as a single reported transaction under that plan.